Heart failure treatment in the elderly

References

• Roger VL, Go AS, Lloyd-Jones DM et al. Heart disease and stroke statistics: 2011 update: a report from the American Heart Association. Circulation123(4), e18–e209 (2011).
   PubMed Web of Science ®Google Scholar
• Maisel A, Mueller C, Adams K et al. State of the art: using natriuretic peptide levels in clinical practice. Eur. J. Heart Fail.10(9), 824–839 (2008).
   PubMed Web of Science ®Google Scholar
• deFilippi CR, Christenson RH, Gottdiener JS, Kop WJ, Seliger SL. Dynamic cardiovascular risk assessment in elderly people: the role of repeated N-terminal pro B-type natriuretic peptide testing. J. Am. Coll. Cardiol.55(5), 441–450 (2010).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Clopton P, Krishnaswamy P et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the breathing not properly (BNP) multinational study. Am. Heart J.147(6), 1078–1084 (2004).
   PubMed Web of Science ®Google Scholar
• Bean JF, Kiely DK, Leveille SG et al. The 6-minute walk test in mobility-limited elders: what is being measured? J. Gerontol.57A(11), M751–M756 (2002).
   Google Scholar
• Shih H, Lee B, Lee RJ, Boyle AJ. The aging heart and post-infarction left ventricular remodeling. J. Am. Coll. Cardiol.57(1), 9–17 (2011).
   PubMedGoogle Scholar
• Sangaralingham SJ. Myocardial fibrosis and CNP with age. Hypertension57, 201 (2011).
   PubMed Web of Science ®Google Scholar
• Kinney JM. Nutritional frailty, sarcopenia and falls in the elderly. Curr. Opin. Clin. Nutr. Metab. Care7(1), 15–20 (2004).
   PubMed Web of Science ®Google Scholar
• Rozzini R, Sabatini T, Frisoni GB, Trabucchi M. Frailty is a strong modulator of heart failure-associated mortality. Arch. Intern. Med.163(6), 737–738; author reply 738 (2003).
   PubMedGoogle Scholar
• Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. MS6A(7), M146–M156 (2001).
   Google Scholar
• Chiarantini D, Volpato S, Sioulis F et al. Lower extremity performance measures predict long term prognosis in older patients hospitalized for heart failure. J. Card. Fail.16, 390–395 (2010).
   PubMed Web of Science ®Google Scholar
• Pulignano G, Del Sindaco D, Tavazzi L et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am. Heart J.143(1), 45–55 (2002).
   PubMed Web of Science ®Google Scholar
• Rich MW. Management of heart failure in the elderly. Heart Fail. Rev.7(1), 89–97 (2002).
   PubMedGoogle Scholar
• Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. Arch. Intern. Med.157(19), 2242–2247 (1997).
   PubMed Web of Science ®Google Scholar
• Heiat A, Gross CP, Krumholz HM. Representation of the elderly, women, and minorities in heart failure clinical trials. Arch. Intern. Med.162(15), 1682–1688 (2002).
   PubMedGoogle Scholar
• Bierman AS. Coexisting illness and heart disease among elderly Medicare managed care enrollees. Health Care Financ. Rev.25(4), 105–117 (2004).
   PubMedGoogle Scholar
• Holland DJ, Kumbhani DJ, Ahmed SH, Marwick TH. Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction: a meta-analysis. J. Am. Coll. Cardiol.57(16), 1676–1686 (2011).
   PubMed Web of Science ®Google Scholar
• Lainscak M, Moullet C, Schon N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int. J. Cardiol.122(2), 149–155 (2007).
   PubMed Web of Science ®Google Scholar
• Aronow WS. Epidemiology, pathophysiology, prognosis, and treatment of systolic and diastolic heart failure in elderly patients. Heart Dis.5(4), 279–294 (2003).
   PubMedGoogle Scholar
• Flather MD, Shibata MC, Coats AJ et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur. Heart J.26(3), 215–225 (2005).
   PubMed Web of Science ®Google Scholar
• Ambrosio G FM, Bohm M et al. β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart97(3), 209–214 (2011).
   PubMed Web of Science ®Google Scholar
• Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur. J. Heart Fail.3(4), 469–479 (2001).
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Gottlieb S, Ghali JK, Waagstein F, Wikstrand JC. Efficacy, safety and tolerability of β-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur. Heart J.25(15), 1300–1309 (2004).
   PubMed Web of Science ®Google Scholar
• Krum H, Hill J, Fruhwald F et al. Tolerability of β-blockers in elderly patients with chronic heart failure: the COLA II study. Eur. J. Heart Fail.8(3), 302–307 (2006).
   PubMed Web of Science ®Google Scholar
• Witham MD, Gillespie ND, Struthers AD. Age is not a significant risk factor for failed trial of beta-blocker therapy in older patients with chronic heart failure. Age Ageing33(5), 467–472 (2004).
   PubMedGoogle Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA273(18), 1450–1456 (1995).
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet355(9215), 1575–1581 (2000).
   PubMed Web of Science ®Google Scholar
• Cleland Jgf TM, Adamus J, Freemantle N, Polonski L, Taylor, J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur. Heart J.27, 2338–2345 (2006).
   PubMedGoogle Scholar
• Ferrari R. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch. Intern. Med.166(6), 659–666 (2006).
   PubMed Web of Science ®Google Scholar
• Hutcheon SD, Gillespie ND, Crombie IK, Struthers AD, Mcmurdo ME. Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial. Heart88(4), 373–377 (2002).
   PubMedGoogle Scholar
• Sumukadas D, Witham MD, Struthers AD, Mcmurdo MET. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. Can. Med. Assoc. J.177(8), 867–874 (2007).
   PubMed Web of Science ®Google Scholar
• Dulin BR. Drug therapy of chronic heart failure in the elderly: the current state of clinical-trial evidence. Curr. Opin. Cardiol.21, 393–399 (2006).
   PubMedGoogle Scholar
• Baruch L, Glazer RD, Aknay N et al. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J.148(6), 951–957 (2004).
   PubMedGoogle Scholar
• O’Meara E, Solomon S, McMurray J et al. Effect of candesartan on New York Heart Association functional class. Eur. Heart J.35, 1920–1926 (2004).
   Google Scholar
• Massie BM, Carson PE, McMurray JJ et al.; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med.359, 2456–2467 (2008).
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet349(9054), 747–752 (1997).
   PubMed Web of Science ®Google Scholar
• Simpson KL. Losartan: a review of its use, with special focus on elderly patients. Drugs Aging3, 227–250 (2000).
   Google Scholar
• Pitt B, Poole-Wilson PA, Segal R et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial: the Losartan Heart Failure Survival Study ELITE II. Lancet355(9215), 1582–1587 (2000).
   PubMed Web of Science ®Google Scholar
• Damman K, Ng Kam Chuen MJ, Macfadyen RJ et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. J. Am. Coll. Cardiol.57(22), 2233–2241
   PubMedGoogle Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med.341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation100, 2312–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation112(25), 3958–3968 (2005).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Nicholls MG. Biomarker-guided treatment of heart failure: still waiting for a definitive answer. J. Am. Coll. Cardiol.56(25), 2101–2104 (2010).
   PubMedGoogle Scholar
• Lainchbury JG, Troughton RW, Strangman KM et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J. Am. Coll. Cardiol.55(1), 53–60 (2009).
   PubMed Web of Science ®Google Scholar
• Howard PA, Dunn MI. Severe musculoskeletal symptoms during continuous infusion of bumetanide. Chest111(2), 359–364 (1997).
   PubMedGoogle Scholar
• Felker GM LK, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med.364(9), 797–805 (2011).
   PubMed Web of Science ®Google Scholar
• Howard PA, Dunn MI. Severe heart failure in the elderly: potential benefits of high-dose and continuous infusion diuretics. Drugs Aging19(4), 249–256 (2002).
   PubMedGoogle Scholar
• Zannad F. Randomized trial of eplerenone in mild heart failure. N. Engl. J. Med. (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Tresch DD, Mcgough MF. Heart failure with normal systolic function: a common disorder in older people. J. Am. Geriatr. Soc.43(9), 1035–1042 (1995).
   PubMedGoogle Scholar
• Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol.53(15), e1–e90 (2009).
   Google Scholar
• Rich MW, Mcsherry F, Williford WO, Yusuf S. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J. Am. Coll. Cardiol.38(3), 806–813 (2001).
   PubMed Web of Science ®Google Scholar
• Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. PROVED Investigative Group. J. Am. Coll. Cardiol.22(4), 955–962 (1993).
   PubMed Web of Science ®Google Scholar
• Packer M, Gheorghiade M, Young JB et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE study. N. Engl. J. Med.329(1), 1–7 (1993).
   PubMed Web of Science ®Google Scholar
• Chun J, Chodosh J. Controversy in heart failure management: digoxin use in the elderly. J. Am. Med. Dir. Assoc.7(9), 581–586 (2006).
   PubMedGoogle Scholar
• Santangeli P, Di Biase L, Dello Russo A et al. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann. Intern. Med.153(9), 592–599 (2010).
   PubMed Web of Science ®Google Scholar
• Healey JS, Hallstrom AP, Kuck KH et al. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur. Heart J.28(14), 1746–1749 (2007).
   PubMedGoogle Scholar
• Haworth JE, Moniz-Cook E, Clark AL, Wang M, Waddington R, Cleland JG. Prevalence and predictors of anxiety and depression in a sample of chronic heart failure patients with left ventricular systolic dysfunction. Eur. J. Heart Fail.7(5), 803–808 (2005).
   PubMed Web of Science ®Google Scholar
• Sayers SL, Hanrahan N, Kutney A et al. Psychiatric comorbidity and greater hospitalization risk, longer length of stay, and higher hospitalization costs in older adults with heart failure. J. Am. Geriatr. Soc.55, 1585–1591 (2007).
   PubMedGoogle Scholar
• Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007–2008. NCHS Data Brief42, 1–8 (2010).
   PubMedGoogle Scholar
• Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs30(5), 427–443 (1985).
   PubMed Web of Science ®Google Scholar
• Goodlin SJ. Palliative care in congestive heart failure. J. Am. Coll. Cardiol.54(5), 386–396 (2009).
   PubMed Web of Science ®Google Scholar
• Notarius CF, Morris B, Floras JS. Caffeine prolongs exercise duration in heart failure. J. Card. Fail.12(3), 220–226 (2006).
   PubMed Web of Science ®Google Scholar
• Chua TP, Harrington D, Ponikowski P, Webb-Peploe K, Poole-Wilson PA, Coats AJ. Effects of dihydrocodeine on chemosensitivity and exercise tolerance in patients with chronic heart failure. J. Am. Coll. Cardiol.29(1), 147–152 (1997).
   PubMed Web of Science ®Google Scholar
• Beniaminovitz A, Lang CC, LaManca J, Mancini DM. Selective low-level leg muscle training alleviates dyspnea in patients with heart failure. J. Am. Coll. Cardiol.40(9), 1602–1608 (2002).
   PubMed Web of Science ®Google Scholar
• Goodlin SJ, Quill TE, Arnold RM. Communication and decision-making about prognosis in heart failure care. J. Card. Fail.14(2), 106–113 (2008).
   PubMed Web of Science ®Google Scholar
• Moss AH, Lunney JR, Culp S et al. Prognostic significance of the ‘surprise’ question in cancer patients. J. Palliative Med.13(7), 837–840 (2010).
   PubMed Web of Science ®Google Scholar
• Riegel B, Dickson VV, Cameron J et al. Symptom recognition in elders with heart failure. J. Nurs. Scholar.42(1), 92–100 (2010).
   PubMedGoogle Scholar
• Riegel B, Moser DK, Anker SD et al. State of the Science: promoting self-care in persons with heart failure. Circulation20(12), 1141–1163 (2009).
   Google Scholar